MURANO: a robust, randomized, multicenter, open-label, phase 3 study evaluating the efficacy and safety of VENCLEXTA® + R (VEN+R) vs BR in CLL patients who received at least one prior therapy 2,5

  • Independent Review Committee (IRC)-assessed PFS was the basis for FDA approval of VEN+R 2
  • The VEN+R trial was designed with a fixed treatment duration 2
  • Select inclusion criteria: ≥18 years of age, 1-3 prior lines of therapy, including at least one chemo-containing regimen, and prior bendamustine only if DoR ≥24 months 5
  • Stratification was by 17p deletion status, risk status, and geographic region 5

*28-day cycle.
From Cycle 1, Day 1, in absence of disease progression or unacceptable toxicity.
Patients were characterized as having either high-risk or low-risk CLL. High-risk CLL was defined as 17p deletion or no response to front-line chemotherapy-containing regimen or relapsed ≤12 months after chemotherapy or within 24 months after chemoimmunotherapy. 6

BR=Bendamustine+rituximab; R/R=relapsed/refractory; IV=intravenous; CR=complete response; ORR=overall response rate; OS=overall survival; FDA=US Food and Drug Administration; DoR=duration of response.